Study reveals why many opt out of multiplex testing for cancer-related gene variants
the ONA take:
Many patients do not want the information that comprehensive genetic testing provides, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania and the Basser Center for BRCA in Penn’s Abramson Cancer Center.
In the study, 49 patient participants with a family or personal history that increased their risk for developing breast and other forms of cancer were offered multiplex testing. More than one-third of the participants declined the test because of uncertainty of the results.
Multiplex testing allows for simultaneous analysis of alterations in multiple cancer-related genes, whereas targeted testing focuses on a specific genetic mutations (eg, BRCA1 and BRCA2 gene mutations). However, the significance of alterations in many of the genes analyzed in multiplex testing is unknown.
All 49 participants received counseling on the advantages and disadvantages of the tests. After counseling, 16 participants declined multiplex testing or being told their results.
Of the remaining participants, 16 tested negative for any cancer-related variants, five tested positive, and 12 were found to have gene variants of uncertain significance (meaning that whether the changes are benign or tied to cancers is unclear).
Many patients do not want the information that comprehensive genetic testing provides.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|